Biogen saw its shares surge nearly 40% after surprising analysts by announcing that it plans to file for FDA approval of the Alzheimer’s disease candidate aducanumab, being co-developed with Eisai, despite halting two failed Phase III studies of the drug in March. Biogen now says a new analysis of a larger dataset from the trials showed that one study showed effective pharmacological and clinical activity, a finding supported by a subset of patients from the second study, even though it missed its primary endpoint . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge